(RCUS) Arcus Biosciences - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NYSE (USA) | Market Cap: 2.986m USD | Total Return: 166.9% in 12m
Avg Turnover: 23.8M
Qual. Beats: 0
Rev. Trend: 64.6%
Qual. Beats: 0
Warnings
Share dilution 27.4% YoY
Interest Coverage Ratio -15.8 is critical
Altman Z'' -2.11 < 1.0 - financial distress zone
Choppy Below Avwap Earnings
Tailwinds
Leader
Arcus Biosciences, Inc. (RCUS) is a clinical-stage biopharmaceutical company focused on developing next-generation cancer immunotherapies. Its pipeline targets multiple biological pathways, including HIF-2a, TIGIT, PD-1, and the adenosine axis (CD73 and CD39), with several candidates currently in Phase 2 and Phase 3 clinical trials for lung, gastrointestinal, and pancreatic cancers.
The company utilizes a partnership-heavy business model, maintaining strategic clinical collaborations with major industry players like AstraZeneca to co-develop combination therapies. In the biotechnology sector, clinical-stage companies typically incur high research and development expenses and rely on milestone payments or capital markets for funding prior to achieving commercial product sales.
For a detailed analysis of the companys financial health and valuation metrics, consider reviewing the latest data on ValueRay.
Key assets include Domvanalimab, an anti-TIGIT antibody, and Casdatifan, a HIF-2a inhibitor, both of which represent significant components of the companys oncology portfolio. Based in Hayward, California, the firm continues to expand its research into inflammatory diseases through external discovery partnerships.
- Gilead Sciences partnership provides critical non-dilutive funding and clinical development validation
- Phase 3 Domvanalimab trial results determine competitive standing in anti-TIGIT market
- Clinical data readouts for Casdatifan impact valuation within the renal cell carcinoma space
- High research and development expenditures necessitate consistent milestone payments to sustain operations
| Net Income: -369.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.49 > 0.02 and ΔFCF/TA -22.84 > 1.0 |
| NWC/Revenue: 269.1% < 20% (prev 595.0%; Δ -326.0% < -1%) |
| CFO/TA -0.49 > 3% & CFO -488.0m > Net Income -369.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.04 > 1.5 & < 3 |
| Outstanding Shares: last quarter (125.4m) vs 12m ago 27.44% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 21.92% > 50% (prev 12.20%; Δ 9.73% > 0%) |
| Interest Coverage Ratio: -15.82 > 6 (EBITDA TTM -339.0m / Interest Expense TTM 22.0m) |
| A: 0.64 (Total Current Assets 844.0m - Total Current Liabilities 209.0m) / Total Assets 997.0m |
| B: -1.62 (Retained Earnings -1.61b / Total Assets 997.0m) |
| C: -0.32 (EBIT TTM -348.0m / Avg Total Assets 1.08b) |
| D: 1.11 (Book Value of Equity 524.0m / Total Liabilities 473.0m) |
| Altman-Z'' = -2.11 = D |
| DSRI: 0.09 (Receivables 3.00m/21.0m, Revenue 236.0m/141.0m) |
| GMI: 1.00 (GM 96.19% / 96.45%) |
| AQI: 1.69 (AQ_t 0.12 / AQ_t-1 0.07) |
| SGI: 1.67 (Revenue 236.0m / 141.0m) |
| TATA: 0.12 (NI -369.0m - CFO -488.0m) / TA 997.0m) |
| Beneish M = -2.76 (Cap -4..+1) = A |
As of May 24, 2026, the stock is trading at USD 23.87 with a total of 405,610 shares traded.
Over the past week, the price has changed by -1.47%,
over one month by -11.98%,
over three months by +24.30% and
over the past year by +166.86%.
Arcus Biosciences has received a consensus analysts rating of 4.46. Therefore, it is recommended to buy RCUS.
- StrongBuy: 8
- Buy: 3
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 34.8 | 45.9% |
P/B = 5.4606
Revenue TTM = 236.0m USD
EBIT TTM = -348.0m USD
EBITDA TTM = -339.0m USD
Long Term Debt = 100.0m USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 113.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 13.0m
Net Debt = -709.0m USD (calculated: Debt 113.0m - CCE 822.0m)
Enterprise Value = 2.28b USD (2.99b + Debt 113.0m - CCE 822.0m)
Interest Coverage Ratio = -15.82 (Ebit TTM -348.0m / Interest Expense TTM 22.0m)
EV/FCF = -4.66x (Enterprise Value 2.28b / FCF TTM -489.0m)
FCF Yield = -21.48% (FCF TTM -489.0m / Enterprise Value 2.28b)
FCF Margin = -207.2% (FCF TTM -489.0m / Revenue TTM 236.0m)
Net Margin = -156.4% (Net Income TTM -369.0m / Revenue TTM 236.0m)
Gross Margin = unknown ((Revenue TTM 236.0m - Cost of Revenue TTM 9.00m) / Revenue TTM)
Tobins Q-Ratio = 2.28 (Enterprise Value 2.28b / Total Assets 997.0m)
Interest Expense / Debt = 19.47% (Interest Expense 22.0m / Debt 113.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -274.9m (EBIT -348.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.04 (Total Current Assets 844.0m / Total Current Liabilities 209.0m)
Debt / Equity = 0.22 (Debt 113.0m / totalStockholderEquity, last quarter 524.0m)
Debt / EBITDA = 2.09 (negative EBITDA) (Net Debt -709.0m / EBITDA -339.0m)
Debt / FCF = 1.45 (negative FCF - burning cash) (Net Debt -709.0m / FCF TTM -489.0m)
Total Stockholder Equity = 535.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -34.28% (Net Income -369.0m / Total Assets 997.0m)
RoE = -17.18% (Net Income TTM -369.0m / Total Stockholder Equity 2.15b)
RoCE = -15.48% (EBIT -348.0m / Capital Employed (Equity 2.15b + L.T.Debt 100.0m))
RoIC = -40.05% (negative operating profit) (NOPAT -274.9m / Invested Capital 686.4m)
WACC = 12.64% (E(2.99b)/V(3.10b) * Re(12.54%) + D(113.0m)/V(3.10b) * Rd(19.47%) * (1-Tc(0.21)))
Discount Rate = 12.54% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.88 | Cagr: 25.67%
[DCF] Fair Price = unknown (Cash Flow -489.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.17 | # QB: 0
Revenue Correlation: 64.58 | Revenue CAGR: 28.15% | SUE: -0.23 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.81 | Chg30d=+0.41% | Revisions=+20% | Analysts=5
EPS next Quarter (2026-09-30): EPS=-0.83 | Chg30d=+12.72% | Revisions=+43% | Analysts=5
EPS current Year (2026-12-31): EPS=-3.52 | Chg30d=+3.56% | Revisions=-14% | GrowthEPS=-7.0% | GrowthRev=-70.3%
EPS next Year (2027-12-31): EPS=-3.12 | Chg30d=+10.49% | Revisions=-14% | GrowthEPS=+11.2% | GrowthRev=+30.1%
[Analyst] Revisions Ratio: +43%